CY1120474T1 - Χημικες ενωσεις - Google Patents

Χημικες ενωσεις

Info

Publication number
CY1120474T1
CY1120474T1 CY20181100009T CY181100009T CY1120474T1 CY 1120474 T1 CY1120474 T1 CY 1120474T1 CY 20181100009 T CY20181100009 T CY 20181100009T CY 181100009 T CY181100009 T CY 181100009T CY 1120474 T1 CY1120474 T1 CY 1120474T1
Authority
CY
Cyprus
Prior art keywords
chemical compounds
compounds
pharmaceutically
processes
formula
Prior art date
Application number
CY20181100009T
Other languages
English (en)
Inventor
Nadim AKHTAR
Robert Hugh Bradbury
David Buttar
Gordon Stuart Currie
Christopher De Savi
Craig Samuel Donald
Richard Albert NORMAN
Matthew OSBORNE
Alfred Arthur Rabow
Heather Marie REDFEARN
Helen Elizabeth WILLIAMS
Neda YAVARI
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1120474T1 publication Critical patent/CY1120474T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Η εφεύρεση αφορά σε ενώσεις του Τύπου (I) ή φαρμακευτικώς-αποδεκτό άλατα αυτών, όπου τα R1 έως R5 έχουν οποιαδήποτε από τις σημασίες που ορίζεται προηγουμένως στην παρούσα περιγραφή· διαδικασίες για την παρασκευή τους, φαρμακευτικές συνθέσεις που τις περιέχουν και τη χρήση τους στη θεραπευτική αντιμετώπιση των κυτταρικών πολλαπλασιαστικών διαταραχών.
CY20181100009T 2013-05-28 2018-01-03 Χημικες ενωσεις CY1120474T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361827951P 2013-05-28 2013-05-28
US201361915685P 2013-12-13 2013-12-13
PCT/GB2014/051607 WO2014191726A1 (en) 2013-05-28 2014-05-27 Chemical compounds

Publications (1)

Publication Number Publication Date
CY1120474T1 true CY1120474T1 (el) 2019-07-10

Family

ID=50841880

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100009T CY1120474T1 (el) 2013-05-28 2018-01-03 Χημικες ενωσεις

Country Status (35)

Country Link
US (4) US9155727B2 (el)
EP (2) EP3004090B1 (el)
JP (1) JP6286031B2 (el)
KR (1) KR20160013198A (el)
CN (1) CN105229004B (el)
AP (1) AP2015008858A0 (el)
AU (1) AU2014272856B2 (el)
BR (1) BR112015029455A8 (el)
CA (1) CA2911859A1 (el)
CL (1) CL2015003491A1 (el)
CR (1) CR20150629A (el)
CY (1) CY1120474T1 (el)
DK (1) DK3004090T3 (el)
DO (1) DOP2015000274A (el)
ES (1) ES2654161T3 (el)
HK (1) HK1222859A1 (el)
HR (1) HRP20171961T1 (el)
HU (1) HUE035738T2 (el)
IL (1) IL242559B (el)
LT (1) LT3004090T (el)
ME (1) ME02892B (el)
MX (1) MX361538B (el)
NI (1) NI201500167A (el)
PE (1) PE20160874A1 (el)
PH (1) PH12015502615B1 (el)
PL (1) PL3004090T3 (el)
PT (1) PT3004090T (el)
RS (1) RS56678B1 (el)
RU (1) RU2664109C2 (el)
SG (1) SG11201509393VA (el)
SI (1) SI3004090T1 (el)
TN (1) TN2015000516A1 (el)
TW (1) TWI653235B (el)
UY (1) UY35590A (el)
WO (1) WO2014191726A1 (el)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190007106A (ko) 2011-12-21 2019-01-21 노비라 테라퓨틱스, 인코포레이티드 B형 간염의 항바이러스성 제제
BR112015004205B1 (pt) 2012-08-28 2022-02-01 Janssen Sciences Ireland Uc Sulfamoil-arilamidas, seu uso das mesmas como medicamentos para o tratamento da hepatite b, composição farmacêutica que as compreende e produto
SI2961732T1 (sl) 2013-02-28 2017-07-31 Janssen Sciences Ireland Uc Sulfamoil-arilamidi in njihova uporaba kot zdravila za zdravljenje hepatitisa B
EP2981536B1 (en) 2013-04-03 2017-06-14 Janssen Sciences Ireland UC N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
ES2695182T3 (es) 2013-05-17 2019-01-02 Janssen Sciences Ireland Uc Derivados de sulfamoil tiofenamida y su uso como medicamentos para tratar la hepatitis B
DK3024819T3 (en) 2013-07-25 2018-06-06 Janssen Sciences Ireland Uc GLYOXAMIDE-SUBSTITUTED PYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B
WO2015059212A1 (en) 2013-10-23 2015-04-30 Janssen R&D Ireland Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US20150216938A1 (en) 2014-02-05 2015-08-06 Novira Therapeutics Inc. Combination therapy for treatment of hbv infections
EA035848B1 (ru) 2014-02-06 2020-08-20 Янссен Сайенсиз Айрлэнд Юси Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
CN118005631A (zh) 2014-12-18 2024-05-10 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
WO2016146591A1 (en) * 2015-03-16 2016-09-22 Astrazeneca Ab Combination treatment
EA201792069A1 (ru) 2015-03-19 2018-04-30 Новира Терапьютикс, Инк. Производные азокана и азонана и способы лечения инфекций гепатита в
MX2017016376A (es) * 2015-06-16 2018-03-02 Jiangsu Hengrui Medicine Co Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo.
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
CN108350062B (zh) 2015-08-06 2022-10-14 达纳-法伯癌症研究所股份有限公司 靶向蛋白降解以减弱过继性t细胞疗法相关的不良炎症反应
CA3000197A1 (en) 2015-09-29 2017-04-06 Novira Therapeutics, Inc. Crystalline forms of a hepatitis b antiviral agent
DK3355884T3 (da) * 2015-10-01 2021-08-02 Olema Pharmaceuticals Inc Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler
KR102099159B1 (ko) * 2015-11-12 2020-04-10 쯔지앙 하이썬 파머슈티컬 컴퍼니, 리미티드 아크릴산 유도체, 그의 제조방법 및 의약에 있어서의 그의 사용방법
CA3008020C (en) 2015-12-09 2024-02-20 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective estrogen receptor downregulators
AU2016379672A1 (en) 2015-12-22 2018-06-21 Jiangsu Hengrui Medicine Co., Ltd. Benzopiperidine derivative, preparation method thereof and medical use thereof
JP6905539B2 (ja) * 2016-02-05 2021-07-21 インベンティスバイオ リミテッド ライアビリティ カンパニー 選択的エストロゲン受容体分解剤およびその使用
CN113717170A (zh) * 2016-04-01 2021-11-30 里科瑞尔姆Ip控股有限责任公司 雌激素受体调节剂
JP2019511542A (ja) 2016-04-15 2019-04-25 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カプシド集合阻害剤を含む組み合わせ及び方法
US10125135B2 (en) 2016-04-20 2018-11-13 Astrazeneca Ab Chemical compounds
JP7131773B2 (ja) * 2016-04-29 2022-09-06 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ホルモン受容体に関連する転写活性の標的尺度
CN109661393A (zh) * 2016-05-08 2019-04-19 上海诚妙医药科技有限公司 帕布昔利布的新晶型及其制备方法及其用途
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN109311876B (zh) * 2016-06-16 2022-05-03 豪夫迈·罗氏有限公司 杂芳基雌激素受体调节剂及其用途
EP3472159A1 (en) 2016-06-16 2019-04-24 F. Hoffmann-La Roche AG TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
WO2018001232A1 (zh) * 2016-06-29 2018-01-04 浙江海正药业股份有限公司 丙烯酸类衍生物及其制备方法和其在医药上的用途
RU2019102647A (ru) 2016-07-01 2020-08-03 Г1 Терапьютикс, Инк. Антипролиферационные средства на основе пиримидина
WO2018019793A1 (en) 2016-07-25 2018-02-01 Astrazeneca Ab N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer
CN107814798B (zh) * 2016-09-14 2020-11-03 四川科伦博泰生物医药股份有限公司 3-取代丙烯酸类化合物及其制备方法和用途
JP7050770B2 (ja) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
SG11201903182XA (en) 2016-10-24 2019-05-30 Astrazeneca Ab 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
JP7229162B2 (ja) 2017-01-06 2023-02-27 ジー１ セラピューティクス， インコーポレイテッド 癌の治療に対する併用療法
WO2018130123A1 (zh) * 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的五环类化合物及其应用
WO2018130124A1 (zh) * 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的三环类化合物及其应用
LT3494116T (lt) * 2017-01-30 2020-01-10 Astrazeneca Ab Estrogeno receptorių moduliatoriai
JP7227912B2 (ja) 2017-02-08 2023-02-24 ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド キメラ抗原受容体の調節
CN110461853A (zh) 2017-02-10 2019-11-15 G1治疗公司 苯并噻吩雌激素受体调节剂
CN108864080B (zh) * 2017-05-09 2021-10-15 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的四环类化合物及其应用
CN110536888B (zh) * 2017-06-20 2022-07-26 江苏恒瑞医药股份有限公司 一种苯并哌啶类衍生物的盐、其晶型及盐、其晶型的制备方法
BR112019027967A2 (pt) 2017-06-29 2020-07-14 G1 Therapeutics, Inc. forma b cristalina isolada, composição farmacêutica, método para o tratamento de um distúrbio, método de um composto ou composição, e, processo para produzir forma b cristalina.
TWI829655B (zh) 2017-10-18 2024-01-21 瑞士商諾華公司 用於選擇性蛋白質降解的組合物及方法
EA038160B1 (ru) * 2017-11-30 2021-07-15 Астразенека Аб Модуляторы рецептора эстрогена
CN109867659A (zh) * 2017-12-04 2019-06-11 江苏恒瑞医药股份有限公司 苯并哌啶类衍生物的制备方法
US10519152B2 (en) * 2017-12-21 2019-12-31 Astrazeneca Ab Compounds and their use in treating cancer
JP7348663B2 (ja) * 2018-02-23 2023-09-21 センター フォー インテリジェント リサーチ イン クリスタル エンジニアリング，エセ．エレ． ユビキノールの共結晶及びそれらを含む組成物
MX2020009531A (es) 2018-03-14 2020-10-05 Janssen Sciences Ireland Unlimited Co Regimen posologico del modulador del ensamblaje de la capside.
WO2019228443A1 (en) * 2018-05-30 2019-12-05 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Selective estrogen receptor downregulators and uses thereof
HUE064542T2 (hu) 2018-06-21 2024-03-28 Hoffmann La Roche A 3-((1R,3R)1(2,6-difluoro-4-((1-(3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9 -tetrahidro-2H-pirido[3,4-b]indol-2-il)-2,2-difluoropropán-1-ol tartarátsó szilárd formái, eljárás elõállításukra és rákos megbetegedések kezelésében történõ alkalmazási módszereik
CN112423743A (zh) 2018-07-03 2021-02-26 伊利诺伊大学评议会 未折叠蛋白反应的激活剂
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN DEGRADATION
EP3902545A4 (en) 2018-12-24 2022-06-22 InventisBio Co., Ltd. NOVEL SALTS OF SELECTIVE ESTROGEN RECEPTOR DEGRADERS
AU2020223865A1 (en) 2019-02-22 2021-07-15 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
EP3959320A1 (en) 2019-04-24 2022-03-02 Novartis AG Compositions and methods for selective protein degradation
JP2022532526A (ja) 2019-05-06 2022-07-15 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Ｈｂｖ感染又はｈｂｖ誘導性疾患の処置において有用なアミド誘導体
US11826430B2 (en) * 2019-05-14 2023-11-28 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CA3148221A1 (en) 2019-08-06 2021-02-11 Recurium Ip Holdings, Llc Estrogen receptor modulators for treating mutants
MX2022005139A (es) * 2019-11-04 2022-06-24 Recurium Ip Holdings Llc Sales y formas de un modulador de receptores estrogénicos.
US11952349B2 (en) 2019-11-13 2024-04-09 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
JP2023509944A (ja) 2020-01-10 2023-03-10 江蘇恒瑞医薬股▲ふん▼有限公司 三環式テトラヒドロイソキノリン誘導体、その調製方法及びその医薬的応用
WO2021253380A1 (en) * 2020-06-19 2021-12-23 InventisBio Co., Ltd. Oral formulations and uses thereof
BR112023002161A2 (pt) * 2020-08-05 2023-04-04 Aizant Drug Res Solutions Private Limited Formas sólidas de dosagem de palbociclibe
EP4247977A2 (en) 2020-11-23 2023-09-27 Sanofi Panel of er regulated genes for use in monitoring endocrine therapy in breast cancer
JP2024502270A (ja) 2020-12-23 2024-01-18 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー エストロゲン受容体調節薬
US11834458B2 (en) 2021-03-23 2023-12-05 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CA3226156A1 (en) * 2021-07-08 2023-01-12 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
TW202317582A (zh) 2021-07-09 2023-05-01 大陸商江蘇恒瑞醫藥股份有限公司 三環四氫異喹啉類衍生物的鹽型
WO2023221123A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Crystalline forms of an estrogen receptor antagonist
WO2024030968A1 (en) 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Compounds for modulating ret protein
WO2024097989A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein degraders
WO2024097980A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein inhibitors

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
AU2381497A (en) 1996-04-19 1997-11-12 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
FR2778404B1 (fr) * 1998-05-06 2000-06-30 Hoechst Marion Roussel Inc Derives du dihydro ou tetrahydronaphtalene, et les compositions pharmaceutiques les renfermant
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
IL145922A0 (en) 1999-04-28 2002-07-25 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
FR2796644B1 (fr) * 1999-07-23 2001-09-07 Adir Nouveaux derives de beta-carboline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2402549A1 (en) * 2000-03-15 2001-09-20 Aventis Pharma Deutschland Gmbh Substituted beta-carbolines
US6720331B2 (en) 2001-04-03 2004-04-13 National Sun Yat-Sen University 1-substituted 1,2,3,4-tetrahydro-β-carboline and 3,4-dihydro-β-carboline and analogs as antitumor agents
JP2005516967A (ja) 2002-01-18 2005-06-09 ザ ジェネティクス カンパニー インコーポレーティッド β−セクレターゼインヒビター
CA2483311A1 (en) 2002-04-22 2003-10-30 Philip A. Beachy Modulators of hedgehog signaling pathways, compositions and uses related thereto
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
US20050004164A1 (en) 2003-04-30 2005-01-06 Caggiano Thomas J. 2-Cyanopropanoic acid amide and ester derivatives and methods of their use
US7872133B2 (en) 2003-06-23 2011-01-18 Ono Pharmaceutical Co., Ltd. Tricyclic heterocycle compound
CN1856461A (zh) * 2003-07-28 2006-11-01 史密丝克莱恩比彻姆公司 作为雌激素受体调节剂的亚环烷基化合物
DE10335725A1 (de) 2003-08-05 2005-03-03 Bayer Cropscience Gmbh Safener auf Basis aromatisch-aliphatischer Carbonsäuredarivate
AU2005206570A1 (en) 2004-01-23 2005-08-04 Novartis Vaccines And Diagnostics, Inc. Tetrahydrocarboline compounds as anticancer agents
BRPI0508540B8 (pt) * 2004-03-11 2021-05-25 Actelion Pharmaceuticals Ltd composto, composição farmacêutica, e, uso de um composto
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
TW200631949A (en) 2004-10-28 2006-09-16 Inst For Pharm Discovery Inc Substituted carboxylic acids
EP1836182A2 (en) 2004-11-18 2007-09-26 The Institutes for Pharmaceutical Discovery, LLC Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors
EP1851219A1 (en) 2005-02-14 2007-11-07 Miikana Therapeutics, Inc. Fused heterocyclic compounds useful as inhibitors of histone deacetylase
CN101175754A (zh) * 2005-03-22 2008-05-07 阿斯利康(瑞典)有限公司 用作CB1受体配体的新四氢-1H-吡啶并[4,3-b]吲哚衍生物
US20070032385A1 (en) 2005-06-20 2007-02-08 Dunetz Joshua R Sustainable chemical processes
BRPI0713096A2 (pt) 2006-05-09 2012-10-16 Hemaquest Pharmaceuticals Inc métodos para tratar distúrbios sangüìneos
HUE033894T2 (en) 2006-08-23 2018-01-29 Kudos Pharm Ltd 2-Methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as MTOR inhibitors
JP2010503615A (ja) 2006-08-29 2010-02-04 レインナーベート リミテッド レチノイド化合物およびそれらの使用
WO2008124838A1 (en) 2007-04-10 2008-10-16 University Of Maryland, Baltimore Compounds that inhibit human dna ligases and methods of treating cancer
WO2008124836A2 (en) 2007-04-10 2008-10-16 Uwm Research Foundation, Inc. Methods of reducing virulence in bacteria
WO2008127714A1 (en) 2007-04-13 2008-10-23 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
EP2178537A4 (en) 2007-07-19 2011-08-17 Merck Sharp & Dohme BETA-CARBOLIN DERIVATIVES AS ANTIDIBLE COMPOUNDS
WO2010002835A2 (en) * 2008-07-03 2010-01-07 Osteogenex, Inc. Vinpocetine and eburnamonine derivatives for promoting bone growth
TW201028414A (en) 2009-01-16 2010-08-01 Merck Sharp & Dohme Oxadiazole beta carboline derivatives as antidiabetic compounds
US20120135089A1 (en) 2009-03-17 2012-05-31 Stockwell Brent R E3 ligase inhibitors
WO2010138706A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating breast cancer
WO2010138758A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating cancer and non-neoplastic conditions
US20140303144A1 (en) 2011-02-18 2014-10-09 Medivation Technologies, Inc. Compounds and methods of treating hypertension
WO2013022740A2 (en) 2011-08-05 2013-02-14 Corning Incorporated Gpr35 ligands and the uses thereof

Also Published As

Publication number Publication date
EP3004090B1 (en) 2017-10-25
US9155727B2 (en) 2015-10-13
CN105229004A (zh) 2016-01-06
KR20160013198A (ko) 2016-02-03
IL242559B (en) 2018-11-29
CR20150629A (es) 2016-04-05
EP3004090A1 (en) 2016-04-13
US20160136140A1 (en) 2016-05-19
AU2014272856B2 (en) 2017-08-17
US20140357661A1 (en) 2014-12-04
TWI653235B (zh) 2019-03-11
NI201500167A (es) 2018-10-18
US9616050B2 (en) 2017-04-11
ES2654161T3 (es) 2018-02-12
TW201536779A (zh) 2015-10-01
US10130617B2 (en) 2018-11-20
LT3004090T (lt) 2018-01-10
UY35590A (es) 2014-11-28
JP6286031B2 (ja) 2018-02-28
HK1222859A1 (zh) 2017-07-14
PH12015502615A1 (en) 2016-02-29
CA2911859A1 (en) 2014-12-04
DK3004090T3 (en) 2018-01-08
PT3004090T (pt) 2017-12-22
ME02892B (me) 2018-04-20
HRP20171961T1 (hr) 2018-02-09
AU2014272856A1 (en) 2015-11-26
DOP2015000274A (es) 2015-12-31
MX2015016428A (es) 2016-03-03
SI3004090T1 (en) 2018-01-31
SG11201509393VA (en) 2015-12-30
MX361538B (es) 2018-12-10
HUE035738T2 (en) 2018-05-28
US20190038607A1 (en) 2019-02-07
JP2016522835A (ja) 2016-08-04
RS56678B1 (sr) 2018-03-30
BR112015029455A8 (pt) 2020-03-17
US20170326115A1 (en) 2017-11-16
EP3360875A1 (en) 2018-08-15
WO2014191726A1 (en) 2014-12-04
PE20160874A1 (es) 2016-09-04
RU2015151502A (ru) 2017-07-04
RU2664109C2 (ru) 2018-08-15
PH12015502615B1 (en) 2016-02-29
CL2015003491A1 (es) 2016-06-03
BR112015029455A2 (pt) 2017-07-25
PL3004090T3 (pl) 2018-02-28
RU2015151502A3 (el) 2018-03-23
TN2015000516A1 (en) 2017-04-06
CN105229004B (zh) 2017-05-03
AP2015008858A0 (en) 2015-11-30

Similar Documents

Publication Publication Date Title
CY1120474T1 (el) Χημικες ενωσεις
CY1124726T1 (el) Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv
CY1120031T1 (el) Αποπτωτικοι υποκινητες ν-ακυλοσουλφοναμιδης
CY1121706T1 (el) Ενωσεις υποκατασταθεισες διυδροϊσοκινολινονης
CY1123627T1 (el) Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου
CY1120734T1 (el) Στερεες μορφες ενος εκλεκτικου αναστολεα cdk4/6
CY1121804T1 (el) Καινοτομες ενωσεις πυριμιδινης και πυριδινης και η χρηση τους
BR112017013491A2 (pt) compostos de pirimidina fundida para o tratamento de hiv
TN2015000313A1 (en) Chemical compounds
EA201790024A1 (ru) Модуляторы toll-подобных рецепторов для лечения вич
EA201690316A1 (ru) Соединения для применения в качестве иммуномодуляторов
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CY1117105T1 (el) Ενωσεις πυριδαζινονης και χρηση τους ως αναστολεις του daao
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
EA201791304A1 (ru) Производные изохинолина для лечения вич
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
CY1122313T1 (el) Ορβεπιταντη για την αγωγη του χρονιου κνησμου
TR201909447T4 (tr) Aramkol tuzları.
EA201890331A1 (ru) Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена
EA201600124A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
EA201600434A1 (ru) Применение производных бензимидазолпролина
EA201650003A1 (ru) Соединённые циклоалкилом дигетероциклические производные